OPRX OptimizeRx Corp

OptimizeRx Partners with Komodo Health to Expand Life Sciences Support at Point-of-Care

OptimizeRx Partners with Komodo Health to Expand Life Sciences Support at Point-of-Care

Komodo’s Extensive Healthcare Map Powers Precise Care Milestone Mapping, Improving Support for Providers and Patients

ROCHESTER, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has partnered with Komodo Health, a data-driven healthcare software company with access to the broadest array of real-world data across patients, practitioners, and health systems. 

The partnership integrates Komodo’s comprehensive with OptimizeRx’s digital health and communication platform to power OptimizeRx’s . The solution leverages automated intelligence through machine-learning and APIs to seamlessly deliver point-of-care messaging.



Komodo’s real-world visibility into millions of patient journeys and healthcare provider actions across all therapeutic areas will enable OptimizeRx to deliver richer insights to physicians through its digital health network. This visibility expands OptimizeRx’s total addressable audience, giving its life science clients unparalleled ability to reach and support clinicians at precise moments at the point-of-care. The API-driven integration supplements OptimizeRx’s recent platform enhancement involving the application of advanced analytics using machine learning methods applied to real-world-data (RWD).



“Accurate, timely, real-world patient insights through digital platforms have become critically important given that COVID-19 has fundamentally changed how providers deliver care,” said Jason Prestinario, head of healthcare solutions at Komodo Health. “Pairing our comprehensive patient insights with OptimizeRx’s powerful provider communications platform will enable a transformative patient experience at the point-of-care.”

As the COVID-19 pandemic has demonstrated, prescribed therapies can change or evolve rapidly. Yet there are few channels currently available that can efficiently reach healthcare providers with timely insights on new therapies and other important care considerations. Scientific advances can also emerge rapidly, but it often takes 10-15 years for an important medical breakthrough to become the standard of care. These gaps can lead to sub-optimal care and outcomes for patients.

“As our digital health footprint expands with more manufacturers coming onto our platform, we continue working relentlessly to steward health data in ways that can efficiently yield better outcomes as well as provide savings for patients,” said Steve Silvestro, chief commercial officer at OptimizeRx. “Our partnership with Komodo Health enables us to augment the physician workflow with actionable insights. By providing additional real-time critical information for clinicians dealing with complex healthcare scenarios, we can improve the patient and physician experience and ultimately treatment outcomes.”

About Komodo Health

Komodo Health believes that smarter, more innovative use of data and analytics is essential for reducing disease burden. We apply advanced data science techniques to our first-of-its-kind Healthcare Map™, which tracks the unique patient journeys of over 320 million patients. Using our cloud-based platform and application suite, we empower a multitude of healthcare stakeholders — life science companies, healthcare payers and providers, patient advocacy groups, and others — to create a more cost-effective, value-driven healthcare system. For more information, visit komodohealth.com.

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on ,  or visit . 

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact 

Doug Baker, CFO

Tel (248) 651-6568 (x807)

 

Media Relations Contact 

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070 

 

Investor Relations Contact 

Ron Both, CMA 

Tel (949) 432-7557 

 



EN
07/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Co...

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. Optimiz...

 PRESS RELEASE

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity R...

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data an...

 PRESS RELEASE

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37% WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company’s in-workflow point-of-care (POC) network, fortify its long-term comp...

 PRESS RELEASE

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases ...

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance -   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan sub...

 PRESS RELEASE

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 202...

OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx manageme...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch